Navigation Links
Agendia Wins 2011 Scrip Award for "Best Partnership Alliance"

IRVINE, Calif. and AMSTERDAM, Feb. 29, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company, today announced that the company is a recipient of the 2011 Scrip Award for "Best Partnership" for its cooperative alliance between Agendia, AstraZeneca and the Netherlands Cancer Institute (NKI). This is the seventh annual competition to recognize and honor achievements throughout the pharmaceutical industry.

The collaboration between Agendia, AstraZeneca and NKI represents a new approach to personalized diagnostics with the goal of accelerating the delivery of promising personalized therapies to patients by segmenting colorectal cancer at the molecular level.

"This is a model of how bio/pharma and academia can work in new paradigms involving a biotech, a pharma and a major academic research center," panel judges on behalf of Scrip said of the partnership. "This has the potential to pioneer new understanding of colorectal cancer and result in new diagnostics to understand a personalized approach to the treatment of this disease that does not now exist."

Scrip, the leading source for global pharmaceutical industry news, gathers highly respected and independent experts from throughout the pharmaceutical industry to recognize innovations across the field including research, clinical trials and breakthrough drugs. The Best Partnership Alliance award acknowledges the importance of partnerships involving pharmaceutical and biotech companies in developing novel therapeutics.

"This award recognizes the unique alliance that brings together high-level academic research as well as companies known for the successful development of molecular diagnostics and targeted therapies," said David Macdonald, Agendia's CEO. "A key feature of this collaboration is that personalized medicine can be developed much more quickly by combining the different expertise of each of the three individual partners from the beginning. The collaboration began in 2011 and is already producing interesting leads."

About Agendia:
Agendia is a leading global commercial molecular diagnostic company that develops and markets genomic-based diagnostic products that improve the quality of life for cancer patients and simplifies complex treatment decisions for their physicians. Agendia's Symphony™ suite of breast cancer products is based on the analysis of hundreds of genes in a patient's breast and provides unprecedented biological insight to address complex treatment decisions. Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint­­, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, a therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo or hormonal therapy, and which patients do not require these treatments and can instead be treated with other less arduous and costly methods.

In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development based on its world-class genomic platform. The company also collaborates with pharmaceutical companies to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.

Agendia was founded in 2003 as a spin-off of the Netherlands Cancer Institute and is based in Irvine, California, United States, and Amsterdam, the Netherlands. For more information, please visit

For further information, please contact:

Ricochet Public Relations
Todd Aydelotte
Tel: +1 212 679 3300

SOURCE Agendia
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendia Introduces the SYMPHONY™ Breast Cancer Profile With Paraffin Embedded Tissue
2. Agendia Appoints New CEO and Supervisory Board Member
3. Agendia Receives €1.27 Million in Funding from the EUs Seventh Framework Programme
4. Agendia Inaugurates New State-of-the-Art Genomics Laboratory in Irvine
5. Agendia to Provide Testimony at Public Meeting on FDA Oversight of Laboratory-Developed Tests
6. Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer
7. FDA Broadens Clearance for Agendias MammaPrint(R)
8. /C O R R E C T I O N -- Agendia B.V./
9. Agendias Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
10. Agendias Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
11. Agendias MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
Post Your Comments:
(Date:10/11/2017)... MENLO PARK, Calif. , Oct. 11, 2017 /PRNewswire/ ... a national scientific team that developed an innovative way ... and quantity of the delivery of new drugs. ... the 2017 Fall Clinical Dermatology Conference will show how ... Massachusetts General Hospital, Harvard Medical School used a suite ...
(Date:10/10/2017)...   West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today shared the results of a study highlighting ... intradermal administration of polio vaccines. The study results were ... 2017 by Dr. Ondrej Mach , Clinical Trials ... (WHO), and recently published in the journal Vaccine. ...
(Date:10/4/2017)... 2017 OBP Medical , a ... devices, today announced regulatory approval from ... Agência Nacional de Vigilância Sanitária (ANVISA)) to market ... retractor with integrated LED light source and smoke ... exposure of a tissue pocket or cavity during ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important ... problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , She developed ... darkness or restricted lighting. As such, it eliminates the need to turn on a ...
(Date:10/13/2017)... ... , ... PurhealthRX , a leading Health and Nutrition Company, is announcing ... full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the ... incorporated into liquid products, while reducing costs to end users. , The team of ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which ... evacuation of the facility as part of a disaster drill on October 3rd. , ... and Shelton City Emergency Manager, as well as the Connecticut Long Term Care ...
(Date:10/13/2017)... York, NY (PRWEB) , ... October 13, 2017 , ... ... influential people in business to advocate for action towards gender equality at their inaugural ... views from around the globe, and reached a social audience of over 3 million. ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
Breaking Medicine News(10 mins):